5-Fluorouracil and interleukin-2 immunochemotherapy enhances immunogenicity of non-small cell lung cancer A549 cells through upregulation of NKG2D ligands

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 9, 2014, Pages 4039-4044

  Zhao, Lei ^a   Wang, Wen Jia ^a   Zhang, Jin Nan ^a   Zhang, Xing Yi ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

5 FU; IL 2; Immunochemotherapy; MICA B; NK cell

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HLA ANTIGEN CLASS 1; INTERLEUKIN 2; MHC CLASS I-RELATED CHAIN A; MICB ANTIGEN; SIGNAL PEPTIDE; ULBP2 PROTEIN, HUMAN;

ANIMAL; BIOSYNTHESIS; CANCER TRANSPLANTATION; CARCINOMA, NON-SMALL-CELL LUNG; CYTOTOXICITY; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; MOUSE; NATURAL KILLER CELL; NUDE MOUSE; PROMOTER REGION; TRANSCRIPTION INITIATION; TUMOR CELL LINE; UPREGULATION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; FLUOROURACIL; GPI-LINKED PROTEINS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOTHERAPY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-2; KILLER CELLS, NATURAL; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROMOTER REGIONS, GENETIC; TRANSCRIPTIONAL ACTIVATION; TRANSPLANTATION, HETEROLOGOUS; UP-REGULATION;

EID: 84902670082     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.9.4039     Document Type: Article

References (27)

1. Ahmed Ali HA, Di J, Mei W, et al (2014). Antitumor activity of lentivirus-mediated interleukin -12 gene modified dendritic cells in human lung cancer in vitro. Asian Pac J Cancer Prev, 15, 611-6.
2. Das D, Preet R, Mohapatra P, et al (2013). 1, 3-Bis (2-chloroethyl)-1-nitrosourea enhances the inhibitory effect of Resveratrol on 5-fluorouracil sensitive/resistant colon cancer cells. World J Gastroenterol, 19, 7374-88.
3. Diefenbach A, Raulet DH (1999). Natural killer cells: stress out, turn on, tune in. Curr Biol, 9, 851-3.
4. Du G, Ye L, Zhang G, et al (2012). Human IL18-IL2 fusion protein as a potential antitumor reagent by enhancing NK cell cytotoxicity and IFN-γ production. J Cancer Res Clin Oncol, 138, 1727-36.
5. Fearon ER, Pardoll DM, Itaya T, et al (1990). Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell, 60, 397-403.
6. Gaffen SL, Liu KD (2004). Overview of interleukin-2 function, production and clinical applications. Cytokine, 28, 109-23.
7. Gasser S, Orsulic S, Brown EJ, et al (2005). The DNA damage pathway regulates innatemimune system ligands for the NKG2D receptor. Nature, 436, 1186-90.
8. Gasser S, Raulet DH (2006). Activation and self-tolerance of natural killer cells. Immunol Rev, 214, 130-42.
9. Holt GE, Podack ER, Raez LE (2011). Immunotherapy as a strategy for the treatment of non-small-cell lung cancer. Therapy, 8, 43-54.
10. Kärre K (2002). NK cells, MHC class I molecules and the missing self. Scand J Immunol, 55, 221-8.
11. Kim JY, Bae JH, Lee SH, et al (2008). Induction of NKG2D ligands and subsequent enhancement of NK cell-mediated lysis of cancer cells by arsenic trioxide. J Immunother, 31, 475-86.
12. Savage P, Costelna D, Moore J, et al (1997). A phase II study of continuous infusional 5-fluorouracil and subcutaneous Interleukin-2 (IL-2) in metastatic renal cancer. Eur J Cancer, 33, 1149-51.
13. Takiuchi H, Ajani JA (1998). Uracil-tegafur in gastric carcinoma: a comprehensive review. J Clin Oncol, 16, 2877-85.
14. Macdonald JS, Astrow AB (2001). Adjuvant therapy of colon cancer. Semin Oncol, 28, 30-40.
15. Moretta A, Bottino C, Vitale M, et al (2001). Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol, 19, 197-223.
16. Ljunggren HG (2008). Cancer immunosurveillance: NKG2D breaks cover. Immunity, 28, 492-4.
17. Makedonas G, Hutnick N, Haney D, et al (2010). Perforin and IL-2 upregulation define qualitative differences among highly functional virus-specific human CD8 T cells. PLoS Pathog, 6, 1000798.
18. Martinez J, Huang X, Yang Y (2010). Direct TLR2 signaling is critical for NK cell activation and function in response to vaccinia viral infection. PLoS Pathog, 6, 1000811.
19. Nausch N, Cerwenka A (2008). NKG2D ligands in tumor immunity. Oncogene, 27, 5944-58.
20. Sandel MH, Speetjens FM, Menon AG, et al (2005). Natural killer cells infiltrating colorectal cancer and MHC class expression. Mol Immunol, 42, 541-6.
21. Siddle HV, Kreiss A, Tovar C, et al (2013). Reversible epigenetic down-regulation of MHC molecules by devil facial tumour disease illustrates immune escape by a contagious cancer. Proc Natl Acad Sci USA, 110, 5103-8.
22. Stella GM, Luisetti M, Pozzi E, et al (2013). Oncogenes in non-small-cell lung cancer: emerging connections and novel therapeutic dynamics. Lancet Respir Med, 1, 251-61.
23. Wang ZX, Cao JX, Liu ZP, et al (2014). Combination of chemotherapy and immnotherapy for colon cancer in China: A meta-analysis. World J Gastroenterol, 20, 1095-106.
24. Xu Y, Wang M (2014). Progress in immunotherapy for non-small cell lung Cancer. Zhongguo Fei Ai Za Zhi, 17, 34-41.
25. Ye L, Fan J, Shi X, et al (2014). Tumor necrosis therapy antibody interleukin-2 fusion protein elicits prolonged and targeted antitumor effects in vivo. Appl Microbiol Biotechnol, 98, 4053-61.
26. Yuan CH, Yang XQ, Zhu CL, et al (2014). Interleukin-7 enhances the in vivo anti-tumor activity of tumor-reactive CD8+ T cells with induction of IFN-gamma in a murine breast cancer model. Asian Pac J Cancer Prev, 15, 265-71.
27. Zheng YW, Li RM, Zhang XW, et al (2013). Current adoptive immunotherapy in non-small cell lung cancer and potential influence of therapy outcome. Cancer Invest, 31, 197-205.